Table 1 Description of overall sample and by systemic failure status at each landmark

From: Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)

Patient characteristics at 1st SRS

Eligible sample N = 104

CNS failure free survival analysis from landmark 1

CNS failure free survival analysis from landmark 2

Total evaluable N = 81

Non-early progression N = 67

Early progression N = 14

Total evaluable N = 65

Non-early progression N = 49

Early progression N = 16

Age, years

 Mean (SE)

58 (1)

59 (1)

58 (1)

65 (3)

60 (1)

60 (1)

58 (4)

 < 60

51 (49)

37 (46)

33 (49)

4 (29)

28 (43)

20 (40)

8 (50)

 ≥ 60

53 (51)

44 (54)

34 (51)

10 (71)

37 (57)

29 (59)

8 (50)

P-valuea

  

P = 0.16

 

P = 0.52

Race

 Asian

5 (5)

4 (5)

4 (5)

0

4 (6)

3 (6)

1 (6)

 Black

11 (11)

10 (12)

10 (15)

0

8 (12)

7 (14)

1 (6)

 White

87 (84)

67 (83)

53 (79)

14 (100)

53 (82)

39 (80)

14 (88)

 Unknown

1 (1)

0

0

0

0

0

0

P-valuea

  

P = 0.17

 

P = 0.85

Hispanic

 Yes

1 (1)

1 (1)

1 (1)

0

0

0

0

 No

99 (95)

77 (95)

63 (94)

14 (100)

62 (95)

47 (96)

15 (94)

 Unknown

4 (4)

3 (4)

3 (4)

0

3 (5)

2 (4)

1 (6)

KPS

 90–100

42 (40)

37 (46)

30 (45)

7 (50)

33 (51)

25 (51)

8 (50)

 70–85

48 (46)

37 (46)

30 (45)

7 (50)

26 (40)

18 (37)

8 (50)

 ≤ 60

12 (12)

5 (6)

5 (7)

0

4 (6)

4 (8)

0

 Unknown

2 (2)

2 (2)

2 (3)

0

2 (3)

2 (4)

0

P-valuea

  

P = 0.75

 

P = 0.50

Hormone Receptors

 ER + / HER2-

45 (43)

35 (43)

27 (40)

8 (57)

25 (38)

17 (35)

8 (50)

 ER- / HER2-

23 (22)

16 (20)

12 (18)

4 (29)

11 (17)

8 (16)

3 (19)

 HER2+

33 (32)

27 (33)

25 (37)

2 (14)

27 (42)

23 (47)

4 (25)

 Unknown

3 (3)

3 (4)

3 (4)

0

2 (3)

1 (2)

1 (6)

P-valuea

  

P = 0.25

 

P = 0.38

Cancer Subtype

 Lumina A

45 (43)

35 (43)

27 (40)

8 (57)

25 (38)

18 (36)

8 (50)

 Lumina B

16 (15)

13 (16)

12 (18)

1 (7)

13 (20)

11 (22)

2 (13)

 HER2 Type

17 (16)

14 (17)

13 (19)

1 (7)

14 (22)

12 (24)

2 (13)

 Basal

23 (22)

16 (20)

12 (18)

4 (29)

11 (17)

8 (16)

3 (19)

 Unknown

3 (3)

3 (4)

3 (4)

0

2 (3)

1 (2)

1 (6)

P-valuea

  

P = 0.41

 

P = 0.57

Brain Mets at SRS

 1

42 (40)

33 (41)

27 (40)

6 (43)

30 (46)

23 (47)

7 (44)

 2–3

31 (30)

23 (28)

19 (28)

4 (29)

18 (28)

12 (24)

6 (38)

 > = 4

30 (30)

24 (30)

20 (30)

4 (29)

16 (26)

14 (29)

2 (13)

 Unknown

1 (1)

1 (1)

1 (1)

0

1 (2)

0

1 (6)

P-valuea

  

P > 0.99

 

P = 0.17

Fraction Number

 1

44 (42)

39 (48)

29 (43)

10 (71)

31 (48)

20 (41)

11 (69)

 3

41 (40)

26 (32)

23 (35)

3 (21)

18 (28)

16 (33)

2 (13)

 5

16 (15)

13 (16)

12 (18)

1 (7)

13 (20)

11 (22)

2 (13)

 missing

3 (3)

3 (4)

3 (4)

0

3 (5)

2 (4)

1 (6)

P-valuea

  

P = 0.27

 

P = 0.21

Planning Target Volume

 mean (SE)

12.4 (1.9)

9.1 (1.2)

9.3 (1.3)

8.5 (3.4)

9.5 (1.4)

9.9 (1.6)

8.2 (3.3)

 median

5.3

4.7

5.0

2.3

5.0

6.8

3.1

 (IQR)

(1.7, 14.0)

(1.6,12.6)

(1.6, 13.2)

(1.2, 6.2)

(1.6, 13.6)

(2.0, 13.9)

(1.2, 6.9)

 missing

5

5

5

0

5

3

2

P-valueb

  

P = 0.39

 

P = 0.29

Systemic Therapy After 1st SRS

 None

12 (12)

6 (7)

6 (9)

0

5 (8)

5 (10)

0

 Chemo +/- endocrine / immunotherapy

42 (40)

34 (42)

25 (37)

9 (64)

22 (34)

13 (27)

9 (56)

 Targeted agents

28 (27)

22 (27)

20 (30)

2 (14)

19 (29)

17 (35)

2 (13)

 Her2 directed +/- chemotherapy

16 (15)

14 (17)

12 (18)

2 (14)

14 (22)

11 (22)

3 (19)

 Antibody drug conjugate

6 (6)

5 (6)

4 (6)

1 (7)

5 (8)

3 (6)

2 (13)

P-valuea

  

P = 0.34

 

P = 0.10

  1. aChi-square test compares the proportions between groups defined by systemic disease status at the landmark.
  2. bWilcoxon Rank Sum test compares the median between groups defined by systemic disease status at the landmark.
Back to article page